Piramal Pharma Limited receives fresh notice from Gujarat Pollution Control Board imposing Rs 1 crore environmental damage compensation on its Dahej site, amid ongoing closure directions under Water Act. Company engages regulators for swift resolution, confirming no material financial or operational impact beyond disclosed amounts.
Piramal Pharma Limited, a key player in India's pharmaceutical sector, disclosed on February 10, 2026, an additional regulatory action from the Gujarat Pollution Control Board (GPCB). This follows the board's earlier closure directive under Section 33-A of the Water (Prevention and Control of Pollution) Act, 1974, targeting the company's Dahej manufacturing facility at Plot No. D-2/11/A/1, GIDC Dahej, Taluka-Vagra, District-Bharuch, Gujarat 392130.
The latest development involves an interim environmental damage compensation (EDC) of Rs 1 crore, notified directly at the Dahej site. This builds on prior communications dated February 4, 2026, highlighting GPCB's pollution control measures for pharma plants in Gujarat's industrial hubs like GIDC Dahej.
Piramal Pharma reaffirms its proactive stance, collaborating with authorities and adhering to Hon’ble courts' guidance for expedited resolution on GPCB closure and water pollution compliance.
Key Developments
-
GPCB imposes Rs 1 crore interim EDC on February 10, 2026, at Dahej pharma plant.
-
Closure directions issued earlier under Water (Prevention & Control of Pollution) Act, 1974.
-
No material impact on Piramal Pharma's finances, operations, or other activities beyond EDC and prior bank guarantee.
-
Company pursues regulatory resolution per court directives.
This update underscores ongoing environmental compliance challenges for Gujarat pharma manufacturers amid stricter GPCB enforcement on industrial pollution control.
Source: Piramal Pharma Limited BSE/NSE Filing under SEBI Regulation 30 GPCB Official Notice